Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

详细信息    查看全文

• 作者：Bruce E. Strober ; MD ; PhD^a ; ^b ; ^{strober@uchc.edu" class="auth_mail" title="E-mail the corresponding author} ; Robert Bissonnette ; MD^c ; David Fiorentino ; MD ; PhD^d ; Alexa B. Kimball ; MPH ; MD^e ; Luigi Naldi ; MD^f ; Neil H. Shear ; MD^g ; Kavitha Goyal ; MD^h ; Steven Fakharzadeh ; MD ; PhD^h ; Stephen Calabro ; MS^h ; Wayne Langholff ; PhDⁱ ; Yin You ; MSⁱ ; Claudia Galindo ; MD^h ; Seina Lee ; MS ; PharmD^j ; Mark G. Lebwohl ; MD^k
• 关键词：adalimumab ; biologic ; BSA ; DLQI ; effectiveness ; efficacy ; etanercept ; infliximab ; PGA ; PSOLAR ; Psoriasis Longitudinal Assessment and Registry ; ustekinumab
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：74
• 期：5
• 页码：851-861.e4
• 全文大小：1224 K

文摘

Comparing effectiveness of biologics in real-world settings will help inform treatment decisions.

Objectives

We sought to compare therapeutic responses among patients initiating infliximab, adalimumab, or etanercept versus ustekinumab during the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Methods

Proportions of patients achieving a Physician Global Assessment score of clear (0)/minimal (1) and mean decrease in percentage of body surface area with psoriasis were evaluated at 6 and 12 months. Adjusted logistic regression (Physician Global Assessment score 0/1) and analysis of covariance (percentage of body surface area with psoriasis) were performed to determine treatment factors associated with effectiveness.

Results

Of 2541 new users on registry, 2076 had efficacy data: ustekinumab (n = 1041), infliximab (n = 116), adalimumab (n = 662), and etanercept (n = 257). Patients receiving tumor necrosis factor-alpha(-α) inhibitors were significantly less likely to achieve Physician Global Assessment score 0/1 versus ustekinumab (infliximab [odds ratio {OR} 0.396, P < .0001], adalimumab [OR 0.686, P = .0012], etanercept [OR 0.554, P = .0003] at 6 months and infliximab [OR 0.449, P = .0040] at 12 months). Mean decrease in percentage of body surface area with psoriasis was significantly greater for ustekinumab versus adalimumab (point estimate 1.833, P = .0020) and etanercept (point estimate 3.419, P < .0001) at 6 months and versus infliximab (point estimate 3.945, P = .0005) and etanercept (point estimate 2.778, P = .0007) at 12 months.

Limitations

Treatment selection bias and limited data for doing adjustments are limitations.

Conclusions

In PSOLAR, effectiveness of ustekinumab was significantly better versus all 3 tumor necrosis factor-α inhibitors studied for the majority of comparisons at 6 and 12 months.